DelveInsight’s “Chemotherapy-induced Peripheral Neuropathy (CIPN) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Chemotherapy-induced Peripheral Neuropathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Chemotherapy-induced Peripheral Neuropathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Chemotherapy-induced Peripheral Neuropathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Chemotherapy-induced Peripheral Neuropathy (CIPN): An Overview
CIPN is a frequent, dose-dependent complication of anticancer drugs, including platinum, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors. CIPN occurs in ~20% of patients given standard doses of chemotherapy and in almost 100% of patients treated with high doses.
CIPN presents clinically as deficits in sensory, motor, and sometimes autonomic function. Sensory disturbances range from a mild tingling sensation to spontaneous burning pain and hypersensitivity to stimuli. These symptoms often affect both hands and feet and may spread into a ‘glove/stocking’ distribution. Symptoms are usually symmetrical distally but may be more severe unilaterally. Although dependent on the specific agent, the feet are often affected first
Chemotherapy-induced Peripheral Neuropathy (CIPN) Market Key Facts
-
The market size of chemotherapy-induced peripheral neuropathy in the US was ~USD 900 million in 2022.
-
Among EU4 and the UK, Germany had the highest market size for chemotherapy-induced peripheral neuropathy, i.e., ~USD 125 million, in 2022. The smallest market size was estimated in Spain, with ~USD 50 million in 2022.
-
The total incident population of chemotherapy-induced peripheral neuropathy in the 7MM was ~1,619,000 in 2022.
-
Among the European countries, Germany had the highest incident population of chemotherapy-induced peripheral neuropathy with ~175,000 cases, followed by France, which had ~131,500 incident cases in 2022.
-
Japan had ~310,000 incident cases of chemotherapy-induced peripheral neuropathy in 2022.
-
In terms of severity, most patients have been diagnosed with moderate severity. This was followed by mild severity; the least number was observed for severe cases.
-
Most chemotherapy-induced peripheral neuropathy cases are caused by platinum-based chemotherapeutic agents followed by taxane agents. The fewest cases were observed with other chemotherapeutic agents (except platinum, taxane, and vinca alkaloid).
Chemotherapy-induced Peripheral Neuropathy (CIPN) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Chemotherapy-induced Peripheral Neuropathy pipeline therapies. It also thoroughly assesses the Chemotherapy-induced Peripheral Neuropathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Chemotherapy-induced Peripheral Neuropathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Chemotherapy-induced Peripheral Neuropathy (CIPN) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Chemotherapy-induced Peripheral Neuropathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Chemotherapy-induced Peripheral Neuropathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Chemotherapy-induced Peripheral Neuropathy Epidemiology, Segmented as –
-
Total Incident population of CIPN in the 7MM [2019–2032]
-
Severity-specific Incident population of CIPN in the 7MM [2019–2032]
-
Incident population of CIPN by Chemotherapeutic Agents in the 7MM [2019–2032]
-
Incident population of CIPN by Cancer Type in the 7MM [2019–2032]
Chemotherapy-induced Peripheral Neuropathy (CIPN) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Chemotherapy-induced Peripheral Neuropathy market or expected to be launched during the study period. The analysis covers the Chemotherapy-induced Peripheral Neuropathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Chemotherapy-induced Peripheral Neuropathy drugs based on their sale and market share.
The report also covers the Chemotherapy-induced Peripheral Neuropathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Chemotherapy-induced Peripheral Neuropathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Chemotherapy-induced Peripheral Neuropathy Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/cipn-market
Chemotherapy-induced Peripheral Neuropathy (CIPN) Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Chemotherapy Induced Peripheral Neuropathy (CIPN). Currently, MediciNova is leading the therapeutics market with its Chemotherapy Induced Peripheral Neuropathy (CIPN) drug candidates in the most advanced stage of clinical development.
Chemotherapy-induced Peripheral Neuropathy (CIPN) Companies Actively Working in the Therapeutics Market Include
AlgoTx, Ananda Hemp, Inc. (Ananda Professional), AnnJi Pharmaceutical, Aptinyx, Asahi Kasei, Asahi Kasei Pharma Corp., EA Pharma, Enveric Biosciences, Laboratorios Dr. Esteve S.A. (ESTEVE), Main Line Health, MediciNova, NeuroBo Pharmaceuticals, Regenacy Pharmaceuticals, Solasia Pharma, Sonnet Biotherapeutics Holdings, Toray, WEX Pharmaceuticals, and others.
Emerging and Marketed Chemotherapy-induced Peripheral Neuropathy (CIPN) Therapies Covered in the Report Include:
-
MN-166 (ibudilast): MediciNova
-
ART-123: Asahi Kasei Pharma Corp.
-
HALNEURON (TETRODOTOXIN or TTX): WEX Pharmaceuticals
-
ATX01: AlgoTx
And Many Others
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/cipn-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Chemotherapy-induced Peripheral Neuropathy Competitive Intelligence Analysis
4. Chemotherapy-induced Peripheral Neuropathy Market Overview at a Glance
5. Chemotherapy-induced Peripheral Neuropathy Disease Background and Overview
6. Chemotherapy-induced Peripheral Neuropathy Patient Journey
7. Chemotherapy-induced Peripheral Neuropathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Chemotherapy-induced Peripheral Neuropathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Chemotherapy-induced Peripheral Neuropathy Unmet Needs
10. Key Endpoints of Chemotherapy-induced Peripheral Neuropathy Treatment
11. Chemotherapy-induced Peripheral Neuropathy Marketed Therapies
12. Chemotherapy-induced Peripheral Neuropathy Emerging Drugs and Latest Therapeutic Advances
13. Chemotherapy-induced Peripheral Neuropathy Seven Major Market Analysis
14. Attribute Analysis
15. Chemotherapy-induced Peripheral Neuropathy Market Outlook (In US, EU5, and Japan)
16. Chemotherapy-induced Peripheral Neuropathy Companies Active in the Market
17. Chemotherapy-induced Peripheral Neuropathy Access and Reimbursement Overview
18. KOL Views on the Chemotherapy-induced Peripheral Neuropathy Market
19. Chemotherapy-induced Peripheral Neuropathy Market Drivers
20. Chemotherapy-induced Peripheral Neuropathy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/cipn-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Intracardiac Echocardiography Devices Market
“Intracardiac Echocardiography Devices Market Insight, Competitive Landscape, and Market Forecast, 2028” report delivers an in-depth understanding of historical and forecasted Intracardiac Echocardiography Devices market size, share, and trends globally, which comprises North America, Europe, APAC, and RoW. Moreover, it covers the key companies, emerging products, and commercial & regulatory development, in the Intracardiac Echocardiography Devices Market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/